Loading...

Εκπαιδευτικά προγράμματα

Καταχωρήθηκε: Πέμπτη 05 Μάρ 2020
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas
Καταχωρήθηκε: Τρίτη 03 Μάρ 2020
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas
Καταχωρήθηκε: Τετάρτη 26 Φεβ 2020
https://ashpublications.org/blood/article/doi/10.1182/blood.2019003471/430032/Mutational-profile-and-benefit-of-gemtuzumab Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas
Καταχωρήθηκε: Δευτέρα 24 Φεβ 2020
Our clinical practice and SOP for AML elderly just published. https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2019003662/429643/Is-There-an-Optimal-Conditioning-for-Older?redirectedFrom=fulltext Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas
Καταχωρήθηκε: Πέμπτη 20 Φεβ 2020
https://ashpublications.org/blood/article/doi/10.1182/blood.2019002959/430249/Molecular-MRD-status-and-outcome-after Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas
Καταχωρήθηκε: Δευτέρα 17 Φεβ 2020
Λοιμώξεις από JCV και BKV σε ανοσοκατεσταλμένους ασθενείς. Presenter: Dr Liga Participants: Prof.Spyridonidis, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas
Καταχωρήθηκε: Δευτέρα 27 Ιαν 2020
Discrepancies between premortem clinical diagnoses and postmortem  autopsy diagnoses were evaluated. Of 185 patients who underwent autopsy,  35 patients (18.8%) had a total of 41 missed infections. Five patients (2.7%) had >1 missed infection. Of the 41 missed infections, 18 (43.9%) were viral, 16 (39.0%) were fungal, 5 (12.2%) were...
Καταχωρήθηκε: Τετάρτη 22 Ιαν 2020
We decided a policy change  and accorrdigly we write the new SOP. MM  patients will receive non cryopreserved stem cell grafts. Presenter: Prof. Spyridondiis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Verigou
Καταχωρήθηκε: Παρασκευή 17 Ιαν 2020
A phase II study if vedo in GvHD prevention was presented. This is of  major importance since we run the phase III vedo study. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Verigou
Καταχωρήθηκε: Τρίτη 10 Δεκ 2019
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Verigou
Καταχωρήθηκε: Δευτέρα 02 Δεκ 2019
Results of the Prospective Randomized HOVON-96 Trial in Recipients of  Matched Related and Unrelated Donors were presented in ASH 2019, plenary  session PTCY is better than CSI standrd treatment https://ashpublications.org/blood/article-abstract/134/Supplement_1/1/427807/Post-Transplantation-Cyclophosphamide-after?redirectedFrom=fulltext Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Verigou
Καταχωρήθηκε: Δευτέρα 25 Νοέ 2019
General principles - We use the lowest effective dose of prednisone or methylprednisolone. - We use topical therapy to supplement systemic treatment. (eg oral budesonide together with beclomethasone) -We use follow-up endoscopy to evaluate the response to treatment in patients with persistent diarrhea. Absence of clinical or...
Καταχωρήθηκε: Τρίτη 12 Νοέ 2019
NPM1_Spyridonidis_EAE_2019 Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Verigou
Καταχωρήθηκε: Δευτέρα 21 Οκτ 2019
A paper illustrating the hardle in making decisions in BMT. Presenter: Prof. Spyridonidis  Participants: Dr Liga, Dr Spyridis, Dr Verigou 
Καταχωρήθηκε: Παρασκευή 11 Οκτ 2019
Presenter: Dr Liga Participants: Prof.Spyridonidis, Dr Spyridis, Dr Verigou
Καταχωρήθηκε: Τετάρτη 09 Οκτ 2019
A retrospective matched paired analysis of  EBMT shows the superiority in  regards to GFRS of PTCY vs ATG in MMUD transplantation. Prospective  randomized should confirm these reults. Presenter: Prof.A Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Verigou
Καταχωρήθηκε: Πέμπτη 03 Οκτ 2019
In cases of relapse after allo-HCT, up to 50% of patients have cytogenetic or molecular evolution of their disease [15].A recent analysis in patients with MDS suggested that relapse after allo-HCT is driven by subclones evolving from founding clones existing before allo-HCT but harboring new aberrations [11], arguing for clonal...
Καταχωρήθηκε: Δευτέρα 30 Σεπ 2019
Νεότερα δεδομένα στη θεραπευτική αντιμετώπιση της Οξείας Λεμφοβλαστικής Λευχαιμίας με τη σύγχρονη ανοσοθεραπεία. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Verigou
Καταχωρήθηκε: Παρασκευή 20 Σεπ 2019
Long term results of the phase III study were published. They confirm  our practice in  our Tx center Presenter: Prof. Spyridondis Particpants: Dr Liga, Dr Spyridis, Dr Verigou Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic  haemopoietic peripheral blood stem-cell transplantation from  HLA-identical siblings in patients with acute myeloid leukaemia...
Καταχωρήθηκε: Τρίτη 17 Σεπ 2019
Optimal conditioning for ALL. Does it exist?   Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Verigou
Βρέθηκαν 269 αποτελέσματα. Σελίδα 4 από 14
Σελίδα < [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] > >>
 

 

Τηλέφωνα Επικοινωνίας:

 

Γραμματεία MMMO: 2613 603506 (ασθενείς), 2613 604062 (Γραμματεία Διευθυντή) 
Fax : 2613 604066,
email (για ιατρούς): transplant@upatras.gr,
email (για ασθενείς): mmak@upatras.gr
email (για θέματα κλινικών μελετών) : gcppatras@gmail.com
Μονάδα Μεταμόσχευσης (Νοσηλεία): 2613 603 261
Γραφείο Ιατρών: 2613 604064, 2613 604065,
Εφημερεύων Ιατρός: 2610 999111 (τηλ. κέντρο ΠΓΝΠ)

 

βρείτε μας στο χάρτη

 

Login / Sitemap

 

© Copyright 2015 - 2021 Μονάδα Μεταμόσχευσης Μυελού των Οστών Πάτρας